缺血性卒中卫生经济学评价模型结构研究

doi:10.3969/j.issn.1673-5765.2021.03.009

摘要/Abstract

摘要：

目的梳理和提炼现有文献中缺血性卒中卫生经济学评价模型的结构和逻辑，为规范我国缺血性卒中经济学评价模型提供参考和支持。方法系统检索国内外已发表的缺血性卒中卫生经济学评价文献，对现有文献中评价模型的结构特点进行总结和归纳。结果共纳入20篇国内外缺血性卒中卫生经济学评价文献，其中以决策树与马尔科夫相结合的模型最常见，不同的研究基于对疾病发生发展的不同理解，构建了包括3、4、7及更多状态的评价模型。结论应基于缺血性卒中疾病特征和临床治疗路径，对缺血性卒中卫生经济学评价模型进行恰当地规范。

文章导读： 缺血性卒中卫生经济学评价模型结构各异，归纳不同评价模型的基本框架和逻辑，对提高缺血性卒中经济学评价研究的规范性和可靠性具有重要意义。

关键词: 缺血性卒中; 卫生经济学评价; 模型

Abstract:

Objective To review and analyze the health economic evaluation models of ischemic stroke, to provide reference and support for standardizing the health economic evaluation model of ischemic stroke in China. Methods We systematically reviewed the literatures on health economic evaluation of ischemic stroke, and summarized the structure characteristics of the existing models. Results A total of 20 literatures were included. Of the analyzed evaluation models, the model of decision tree combined with Markov was the most common. Due to different understanding for the onset and progression of stroke, different Markov models with 3, 4, 7 or more states were developed. Conclusions It was necessary to standardize the health economic evaluation model of ischemic stroke, which should be constructed based on disease progression features and clinical pathway.

Key words: Ischemic stroke; Health economic evaluation; Model

王芳旭，陶立波. 缺血性卒中卫生经济学评价模型结构研究[J]. 中国卒中杂志, 2021, 16(03): 265-271.

WANG Fang-Xu, TAO Li-Bo. Review on Health Economic Evaluation Models of Ischemic Stroke[J]. Chinese Journal of Stroke, 2021, 16(03): 265-271.

参考文献

[1] 中国卒中学会，中国卒中学会神经介入分会与中华预

防医学会卒中预防与控制专业委员会介入学组. 急性

缺血性卒中血管内治疗中国指南2018[J]. 中国卒中

杂志，2018，13（7）：706-729.

[2] WANG W Z，JIANG B，SUN H X，et al. Prevalence，

incidence，and mortality of stroke in China：results

from a nationwide population-based survey of 480

687 adults[J]. Circulation，2017，135（8）：759-771.

[3] WU S M，WU B，LIU M，et al. Stroke in China：

advances and challenges in epidemiology，prevention，

and management[J]. Lancet Neurol，2019，18（4）：

394-405.

[4] HUSEREAU D，DRUMMOND M，PETROU S，

et al. Consolidated Health Economic Evaluation

Reporting Standards（CHEERS）statement[J/OL].

Eur J Health Econ，2013，14：367-372[2020-07-10].

https：//doi.org/10.1007/s10198-013-0471-6.

[5] PHILIPS Z，GINNELLY L，SCULPHER M，et

al. Review of guidelines for good practice in

decision-analytic modelling in health technology

assessment[J]. Health Technol Assess，2004，8（36）：

iii-iv，ix-xi，1-158.

[6] BOUVY J C，FRANSEN P S S，BAETEN S A，et

al. Cost-effectiveness of two endovascular treatment

strategies vs intravenous thrombolysis[J]. Acta

Neurol. Scand，2013，127（5）：351-359.

[7] KIM A S，NGUYEN-HUYNH M，JOHNSTON S C.

A cost-utility analysis of mechanical thrombectomy

as an adjunct to intravenous tissue-type plasminogen

activator for acute large-vessel ischemic stroke[J].

Stroke，2011，42（7）：2013-2018.

[8] LIBERMAN A L，CHOI H J，FRENCH D D，et

al. Is the cost-effectiveness of stroke thrombolysis affected by proportion of stroke mimics?[J]. Stroke，

2019，50（2）：463-468.

[9] KABORÉ N，MARNAT G，ROUANET F，et

al. Cost-effectiveness analysis of mechanical

thrombectomy plus tissue-type plasminogen

activator compared with tissue-type plasminogen

activator alone for acute ischemic stroke in France[J].

Rev Neurol（Paris），2019，175（4）：252-260.

[10] PIZZO E，DUMBA M，LOBOTESIS K. Cost-utility

analysis of mechanical thrombectomy between 6

and 24 hours in acute ischemic stroke[J]. Int J Stroke，

2020，15（1）：75-84.

[11] AMIRI A，GOUDARZI R，AMIRESMAILI M，et

al. Cost-effectiveness analysis of tissue plasminogen

activator in acute ischemic stroke in Iran[J]. J Med

Econ，2018，21（3）：282-287.

[12] ARONSSON M，PERSSON J，BLOMSTRAND

C，et al. Cost-effectiveness of endovascular

thrombectomy in patients with acute ischemic

stroke[J]. Neurology，2016，86（11）：1053-1059.

[13] KUNZ W G，HUNINK M G，SOMMER W H，et

al. Cost-effectiveness of endovascular stroke therapy：

a patient subgroup analysis from a US healthcare

perspective[J]. Stroke，2016，47（11）：2797-2804.

[14] LOBOTESIS K，VELTKAMP R，CARPENTER

I H，et al. Cost-effectiveness of stent-retriever

thrombectomy in combination with IV t-PA

compared with IV t-PA alone for acute ischemic

stroke in the UK[J]. J Med Econ，2016，19（8）：785-

794.

[15] LEPPERT M H，CAMPBELL J D，SIMPSON J R，

et al. Cost-effectiveness of intra-arterial treatment as

an adjunct to intravenous tissue-type plasminogen

activator for acute ischemic stroke[J]. Stroke，2015，

46（7）：1870-1876.

[16] RUGGERI M，BASILE M，ZINI A，et al. Costeffectiveness

analysis of mechanical thrombectomy

with stent retriever in the treatment of acute ischemic

stroke in Italy[J]. J Med Econ，2018，21（9）：902-

911.

[17] GANESALINGAM J，PIZZO E，MORRIS S，et al.

Cost-utility analysis of mechanical thrombectomy

using stent retrievers in acute ischemic stroke[J].

Stroke，2015，46（9）：2591-2598.

[18] BOUDREAU D M，GUZAUSKAS G F，CHEN

E，et al. Cost-effectiveness of recombinant tissuetype

plasminogen activator within 3 hours of acute

ischemic stroke：current evidence[J]. Stroke，2014，

45（10）：3032-3039.

[19] XIE X Q，LAMBRINOS A，CHAN B，et al.

Mechanical thrombectomy in patients with acute

ischemic stroke：a cost-utility analysis[J/OL]. CMAJ

Open，2016，4（2）：E316-325[2020-07-10].

https：//doi.org/10.9778/cmajo.20150088.

[20] EHLERS L，ANDERSEN G，CLAUSEN L B，et

al. Cost-effectiveness of intravenous thrombolysis

with alteplase within a 3-hour window after acute

ischemic stroke[J]. Stroke，2007，38（1）：85-89.

[21] TUNG C E，WIN S S，LANSBERG M G. Costeffectiveness

of tissue-type plasminogen activator in

the 3- to 4.5-hour time window for acute ischemic

stroke[J]. Stroke，2011，42（8）：2257-2262.

[22] BOUDREAU D M，GUZAUSKAS G，VILLA K

F，et al. Cost-effectiveness of recombinant tissue

plasminogen activator 3-4.5 hours after onset of

acute ischemic stroke in patient subgroups[J]. Am J

Ophthalmol，2013，108（1）：90-91.

[23] 贾羽，刘建民，杨鹏飞，等. ReVive SE机械取栓对比

静脉溶栓治疗中国急性缺血性卒中患者的成本效用

分析[J]. 中国医疗保险，2019，127（4）：61-67.

[24] 潘岳松，王伊龙，廖晓凌，等. 急性缺血性卒中3h内

rt-PA溶栓的成本效用分析[J]. 中国卒中杂志，2016，

11（6）：462-467.

[25] 王芳旭，陶立波，贾世欢，等. 缺血性脑卒中溶栓配

合机械取栓对比单纯溶栓治疗的卫生经济学评价研

究[J]. 中国医疗保险，2019，126（3）：74-80.

[26] 范玉华，姬晓昙，蓝琳芳. 国内脑卒中临床试验疗效

判断方法中改良Rankin评分的应用现状[J]. 中国神

经精神疾病杂志，2015，41（7）：412-415.